About SkylineDX
SkylineDX is a company based in Rotterdam (Netherlands) founded in 2005. SkylineDX offers products and services including Merlin™ Test and SKY92. SkylineDX operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Rotterdam, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Skylinedx Usa, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
European Commission
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SkylineDX
SkylineDX offers a comprehensive portfolio of products and services, including Merlin™ Test and SKY92.
Assesses gene expression for melanoma risk in patients.
Evaluates biomarkers for hemato-oncology conditions.
People of SkylineDX
Unlock access to complete
Unlock access to complete
Funding Insights of SkylineDX
Investors in SkylineDX
SkylineDX has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, European Union and Novalis LifeSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and advisory services are provided for life sciences.
|
Locked | Locked | Locked | |
|
Life-Sciences & Offline focused VC firm funding companies in Netherlands
|
Locked | Locked | Locked | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked |
Investor details for SkylineDX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SkylineDX
Investment portfolio details for SkylineDX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SkylineDX
Detailed financials for SkylineDX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Skylinedx Comparisons
Peer comparison for SkylineDX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SkylineDX
SkylineDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of SkylineDX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Skylinedx
Complete news archive for SkylineDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SkylineDX
SkylineDX was founded in 2005 and raised its 1st funding round 4 years after it was founded.
SkylineDX is headquartered in Rotterdam, Netherlands. It is registered at Rotterdam, South Holland, Netherlands.
Dharminder Chahal is the current CEO of SkylineDX.
SkylineDX was founded in 2005 and is based in Rotterdam, Netherlands. Gene expression profiling tests for personalized medicine are offered in the biotechnology sector. A proprietary Profiler platform is employed, featuring a secure data analysis system for transcriptomics. MMprofiler is utilized for risk stratification of multiple myeloma patients through 92 genes. AML Profiler supports subtyping of acute myeloid leukemia. APprofiler for angina pectoris detection is under development.
SkylineDX's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
SkylineDX offers Merlin™ Test and SKY92.
SkylineDX has 5 investors. Key investors include European Commission, European Union, Novalis LifeSciences, Van Herk Groep, and EQT.